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ABsTRAcT
Emerging antibiotic resistance is one of the most important microbiological issues of the 21st century. This 
poses a query regarding the future use of antibiotics and availability of other promising therapeutic alternatives. 
The awareness about antibiotic misuse has improved insufficiently and is evident by the increased incidences of 
multidrug resistant infections globally. Amongst different antibacterial therapeutic approaches phage therapy has 
created a niche of its own due to continuous use for treatment of human infections in Eastern Europe. Synergistic 
compounds along with phages have also been proposed as a better alternative compared to antibiotics or phage alone 
for treatment of chronic cases and seriously debilitating diseases. As such, why not allow custom made phage therapy 
for treatment of chronic infections? However, the success of phage therapy will depend upon instant availability of 
characterised bacteriophages from bacteriophage banks which may serve as the major catalyst in bringing Phage 
Therapy to main stream treatment alternatives or in combination therapy at least. In the current article we present 
a glimpse of comprehensive approach about utility of bacteriophage banks and further present personalised phage 
therapy in a synergistic role with antibiotics to overcome emerging antimicrobial resistance.
Keywords: Bacteriophage bank, Emerging antimicrobial resistance; Phage therapy; Phage antibiotic synergy; Custom 
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1. InTRoducTIon
 The imminent rise of antimicrobial resistance (AMR) was 
predicted at the time of discovery of antimicrobials itself1,2. 
AMR has become the most important microbiological issue 
of 21st century3-5. In this regard, during year 2017, the Centre 
for Disease Control and Prevention (CDC), USA initiated a 
national educational campaign - “Be antibiotics aware” to 
prevent the misuse of antibiotics by better prescription services 
in human healthcare and animal farms6. However, as newer 
antimicrobials are hard to come by and the present antimicrobial 
agents are proving inefficacious to deal with the problem of 
emerging antimicrobial resistance, the question arises, ‘What if 
not antibiotics?’ To address this question, phage biologists have 
considered ‘Phage therapy’ as a potential tool for treatment of 
infectious diseases and successful treatment of chronic otitis, 
burn wounds, urinary tract infections and diarrhoea have been 
carried out using bacteriophages7-9. One of the key elements 
in phage therapy is search of phages specific to target bacteria 
which can be resolved to a great extent through ‘Phage Bank’. 
A phage bank isolates, characterises, preserves, maintains and 
fulfils need based supply of phages with known attributes. The 
present review summarises the recent applications of phage 
therapy in humans and highlights the role, challenges and 
importance of phage banks in the current scenario of emerging 
antimicrobial resistance.
2. PhAgE ThERAPy As PERsonAlIsEd 
mEdIcInE
Phage Therapy has been used as personalised medicine in 
treatment of critically ill patients. In the case of a 76 year old 
male patient, in year 2018, phage therapy was used for treatment 
of an aortic graft infected with Pseudomonas aeruginosa10. The 
application of a mixture of phage OMKO1 and ceftazidime 
demonstrating synergism were applied at the site of infection 
and it was found to be cured without relapse following a single 
application of this combination. Intravenous and percutaneous 
delivery of phage cocktail resulted in treatment of a 68-year old 
patient infected with multidrug resistant (MDR) Acinetobacter 
baumannii11. Phage therapy was also successful in treatment 
of lungs infected with resistant Burkholderia cepacia in case 
of a young female12. Also, a 16-year-old French male with 
Netherton syndrome (NS) concomitantly having allergy to 
multiple groups of antibiotics (β-lactams, cephalosporins, 
and macrolids) was successfully treated for chronic skin 
infection due to antibiotic resistant Staphylococcus aureus13. 
Though, in most of the cases mentioned here, resistance to 
phage preparations was also observed but it was overcome 
by intelligently tweaking the treatment by substitution with 
another phage cocktail prepared on a custom basis against 
emergent strain or by combination with antibiotics. The readers 
are referred to other important reviews of phage therapy for 
treatment of localised and systemic infections14-16. Thus, the 
phage therapy has proven effective in experimental clinical 
Received : 06 May 2020, Revised : 17 September 2020 
Accepted : 07 October 2020, Online published : 15 October 2020
306
ANAND, et al.: DEF. LIFE SCI. J., VOL. 5, NO. 4, OCTOBER 2020, DOI : 10.14429/dlsj.5.15760
trials and has provided a viable option for treatment of patients 
with seriously debilitating infections as well. Hence, phage 
therapy is now turning out to be a ray of hope as personalised 
medicine for chronic infections.
3. BAcTERIoPhAgE BAnK
A phage bank performs the duties of physical collection, 
characterisation, preservation, demands based supply, and 
fulfils training and knowledge sharing needs related to 
bacteriophage research. It has been observed that majority 
of research groups are interested in bacteriophages against 
ESKAPE pathogens and enterobacteriaceae, owing to their 
higher disease prevalence, involved economic burden and 
severe consequences. Accordingly, out of very few phage banks 
established till date, most have collection of lytic bacteriophages 
against these pathogens17. Research groups involved in 
isolation of bacteriophages against deadly pathogens have been 
working with Mycobacterium sp., Brucella sp., Burkholderia 
sp., Bacillus sp., Clostridium sp., Propionibacterium sp., 
Streptococcus sp., Yersinia sp., Mannheimia sp., etc. due 
to involvement of severe health consequences. The phage 
bank generally keeps enriching the phage collection to 
expand the coverage of maximum strains of a targeted host 
bacterial species with an idea that some phages from the 
collection will be readily available for use against a newly 
emergent strain.
The physical accumulation of bacteriophages always 
remains challenging for any phage bank. As such, different 
methods of preservation have been assessed for maintaining 
phage viability though significant reduction in phage titre is 
observed with every freeze-thaw cycle18,19. As such the phage 
banks face crucial challenges of maintaining previously 
isolated bacteriophages in viable and infective state as well as 
continue isolating and preserving new bacteriophages. Also 
characterisation of bacteriophages for biophysical parameters 
(pH stability, temperature sensitivity, growth characteristics) 
is important with regard to their application in treatment 
or prophylaxis. Phage Banks have an additional activity of 
maintaining a range of strains of the host bacteria, which 
should be characterised for antibiotic sensitivity profile and 
each phage isolate must also be screened for activity against 
different strains of target host in order to depict the lytic 
spectrum. Thus, due to emerging strains of resistant bacteria 
and resurfacing phage therapy, the phage bank actually should 
have a supportive bacterial bank of emerging pathogens so as 
to apply the concept of Phage Therapy in a flawless manner. 
4. RolE of PhAgE BAnKs
The phage bank may play an important role for therapeutic 
purposes by timely presenting a panel of biologically active 
phages which may be screened against case-specific infection 
causing pathogens to select the most virulent or active phage 
against the provocative infectious bacteria. This needs a 
specialised diagnostic laboratory which should be well versed 
with different phage characteristics. A phage biologist prefers 
using lytic phages lacking any virulence, antibiotic resistance 
associated or toxin genes for pursuing the phage therapy. The 
role of the phage repository becomes all the more important 
when a new resistant strain is encountered during the treatment 
regimen as more effort would be involved in enrichment and 
purification of phages against emerging strain (Fig. 1).
The oldest repository of phages is ‘Eliava Phage Therapy 
Center’ at Tbilisi, Georgia which was established in 1923 
by Georgian scientist Georgi Eliava and French Canadian 
phage pioneer Felix d’Herelle. The institute provided phages 
for prophylaxis and treatment of human infections over the 
entire former Soviet Union for public and military forces. 
Since 1990, the Eliava Institute has gathered 600 phages 
and produced phage preparations after extensive preclinical 
and clinical trials for the treatment and prophylaxis of septic 
figure 1. custom made cocktail designing to overcome emerging antimicrobial resistance. 
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and intestinal infections which may be applied by oral, 
intravenous, subcutaneous or nasal route20. The institute 
offers phage treatments in the form of six major preparations: 
PYO, FERSISI, STAPHYLOCOCCAL, SES, INTESTI and 
ENKO in addition to the auto-phage preparation which is 
personalised for an individual patient21. During world war II, 
the institute provided bacteriophage preparations to soldiers 
for gangrene and cholera22,23. Another important centre for 
research on bacteriophages is ‘Phage Therapy Unit’ at Ludwik 
Hirszfeld Institute of Immunology and Experimental Therapy, 
at Wroclaw, Poland. As on today, it operates as an out-patient 
clinic for providing bacteriophage cocktails in consultation 
with a medical specialist for providing phage cocktails for 
severe cases of infections worldwide24-26. Felix d’Herelle 
Reference Centre for Bacterial Viruses was established in 
Canada which has remained a major provider of phages used 
in research27. However, now with the increasing menace of 
antimicrobial resistance, the entire world has realised the 
importance of bacteriophages and many international culture 
collections worldwide have initiated bacteriophage deposits 
including: American Type Culture Collection (ATCC), USA; 
Biological Resource Centre, NITE (NBRC), Japan; Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ), 
Germany; The Netherlands Culture Collection of Bacteria 
(NCCB), Netherlands; China Center for Type Culture 
Collection (CCTCC), National Centre for Veterinary Type 
Cultures (NCVTC), India, etc., which may be of immense 
help in generation of custom-made phage cocktails. Hatfull lab 
phage collection has ~17000 phages against different genera 
and it is the major provider of genome information about 
bacteriophages28. These culture centres will be of immense 
help in generation of custom-made phage cocktails. As an 
exceptional initiative, Phage directory was established in 2017 
to connect laboratories for collaborating research, knowledge 
and ideas related to bacteriophages for their best use especially 
in treatment29. 
5. chAllEngEs In succEssful 
funcTIonIng of A BAcTERIoPhAgE 
BAnK
The bacteriophages have remained less understood in past 
majorly due to overshadowing by antibiotics in Western world. 
Also the phage classification has remained difficult according 
to the rules laid out in the ICTV Code and/or the International 
Code of Virus Classification and Nomenclature (ICVCN) 
and gained momentum only after public availability of next 
generation sequencing data. Lack of detailed information about 
the phages perhaps could be one of the reasons that out of 771 
microbial repositories registered with World Data Centre for 
Microorganisms, very few maintain phage deposits. Major 
challenges with reference to operation of a phage bank have 
been indicated in Fig. 2. One of the most important challenges 
for a phage repository is the method of phage preservation18,30. 
But before pursuing for phage preservation, one must ensure 
that the bacteriophage matches the purity standards which can 
be preliminarily predicted by noting plaque characteristics. 
Phages with different types of plaques are separated and 
purified using three or more rounds of plaque purification 
in top agar using agar overlay technique. However, problem 
arises when the enrichment broth shows two types of plaques 
after agar overlay - one with large size and another with minute 
plaques. In such cases the purification of phage with large sized 
plaques generally becomes difficult. The phage producing 
minute plaques is generally purified by further diluting the 
enrichment broth. Another problem in phage purification may 
be encountered in the cases where the plaque halo tends to 
increase with duration of incubation as has been observed with 
T7 phages particularly in contrast to most of the phages which 
after a period of incubation, assume a certain size and acquire 
a definitive boundary, either with a fuzzy or clear-cut edge31-33. 
Also, before preservation, partial characterisation is must. The 
characterisation in terms of assessment of biological activity 
and decrease in phage titre over a range of temperatures and 
Figure 2.  Bacteriophage Bank: workflow, major activities, challenges and backup sources.
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pH generally helps to generate passport information about the 
phage. It is also recommended to pursue purification of one 
phage at a time to prevent cross-contamination, especially 
when the host is same.
Phage viability and revival are important issues. The 
bacteriophages are affected by different external factors such 
as temperature, pH and ions which may pose undesirable 
effect on phage viability causing damage to structural elements 
(head, tail, envelope), lipid or DNA34. The readers are referred 
to reviews by Jonczyk35, et al. and Jurczak-Kurek36, et al. 
for sensitivity of different bacteriophages to external factors 
such as temperature, acidity, and salinity. It has been observed 
that tailed phages in comparison to tailless phages and those 
with a large capsid diameter (100 nm) survive better than the 
ones with smaller capsid diameter (60 nm). Also the storage 
temperature after addition of glycerol, i.e., freezing or dipping 
in liquid nitrogen (-196 °C) / freeze-drying yields varied results 
for different phages as they show varying sensitivity towards 
freezing temperature. Undesired preservation temperature 
has an adverse effect on phage viability and may completely 
inactivate some bacteriophages vis-à-vis titre may decrease 
with time or with every refreshment step in others34,37. We 
could observe a twofold decrease in phage titre at every 
refreshment step and loss of viability in ~20% cases of phages 
when addition of glycerol in SM buffer was used to preserve 
environmentally isolated bacteriophages at -80 °C. In case of 
some bacteriophages, the plaque characteristics observed after 
revival was not similar as that observed before preservation 
(unpublished data). The phage titre before preservation 
plays critical role as at high titres some bacteriophages tend 
to aggregate and lose their biological activity38,39. All these 
observations point towards the fact that preservation method 
may vary from one phage to another and initially different 
strategies must be tried for each one so as to ensure revival. 
Other issues include the preservation of host bacteria and 
the author suggests a laboratory naming scheme of a phage 
host bacteria in accordance with the laboratory name of the 
corresponding phage. 
6. cusTom mAdE cocKTAIl dEsIgnIng 
of BAcTERIoPhAgEs
Phages have a critical edge in therapeutics owing to 
their inherent properties such as comparatively easy isolation, 
rapid growth kinetics, survivability till availability of host 
and increase in number during therapy without disturbing the 
natural microflora besides being plentiful in nature. However, 
as with every technological development, phage therapy also 
has its own set of challenges which should be addressed for its 
effective application and utilisation. The emergence of phage 
resistant mutants and narrow host range of phages are the 
issues of concern. The phage resistant mutant strains primarily 
arise due to alterations in cell surface receptors mediated phage 
attachment or more typically due to immunity mediated by 
CRISPR mechanism. Nevertheless mutant generation by phase 
variation has also been shown to provide transient resistance to 
phage infection in case of Gram negative bacteria40-42. Different 
phages may recognise different kind of receptors including 
cell wall (mainly murein and teichoic acid), outer membrane 
proteins, flagellar components, pilli, lipopolysaccharides, 
capsular antigens or extracellular matrix structures to which 
they bind via adhesions or receptor binding proteins (RBPs)43-
46. This provides us with a strategy to deal with the issue of 
bacterial mutants through designing phage cocktails wherein 
phages targeting different host receptors or phages against 
mutant strains are included. Further, the cocktails can also 
cover the issue of narrow host range. However, in such a 
condition, the skepticism about selection of multiphage 
resistant host still persists, which may ultimately lead to failure 
of phage therapy and as such the phage therapy may have fate 
akin to antibiotics. The chances of infective phages against the 
‘then emerging bacteria’ will probably always remain owing to 
coevolving arms race amongst bacteria and phages47. Though 
phages are specific in action yet researchers sometimes come 
across phages crossing species barrier suggesting the nested 
pattern of infection - an aspect that is useful for phage therapy. 
In order to pursue on demand isolation of phages, there are 
reports of relatively easy isolation of bacteriophages against 
P. aeruginosa, Salmonella sp., extended spectrum beta-
lactamase (ESBL) Escherichia coli and Klebsiella pneumoniae 
in comparison to phages against vancomycin resistant 
Enterococcus (VRE), A. baumannii strains and methicillin 
resistant Staphylococcus aureus (MRSA) strains48. In our view, 
the sample type may be a critical factor for phage isolation, as 
in our laboratory, we could isolate S. aureus phages relatively 
easily from animal farm soil samples of milking yards in 
comparison to raw community sewage. Looking beyond the 
contemporary phage therapy regimen, phage – antibiotic 
synergy (PAS) i.e. the combined use of antibiotics at suboptimal 
concentration along with phages has also been found to be 
effective. PAS has been found to reverse 100% mortality 
trend in mice caused by vancomycin - resistant Enterococcus 
faecalis and proved effective against P. aeruginosa in vitro49-
50. As a step ahead, recently, a technology to enable rapid, 
accurate, and selection-free construction of synthetic, tailor-
made phages infecting Gram-positive bacteria have been also 
developed51. Such a technology can be of immense help in 
combating emerging antimicrobial resistance (AMR). Thus, 
altogether, phages - in some way or the other, are providing 
better options to move ahead to target emerging antimicrobial 
resistant bacteria.
7. synERgy of PhAgEs wITh oThER 
AnTImIcRoBIAls
Carlton in year 1999 proposed that bacteriophages 
can be used as a valuable adjunct to antibiotics where the 
host bacteria are still susceptible to some of the antibiotics 
however for pan drug resistant bacteria, phage therapy may 
serve as a stand-alone option52. The use of such a combination 
therapy has proved useful in poultry and later Comeau53,  et al. 
demonstrated PAS effect in conjunction with altered cellular 
state and more typically with cellular filamentation majorly 
leading to more rapid production and diffusion of phages53-54. 
PAS effect has been demonstrated for anti-Pseudomonas 
drugs such as piperacillin and ceftazidime, for meropenem, 
ciprofloxacin and tetracycline in Burkholderia cepacia 
complex and for E. coli also50,55,56. Sequential administration of 
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bacteriophages to complement efficacy of antimicrobial agent 
has also been explored as a means to destabilise biofilms in S. 
aureus, Pseudomonas sp. and E. coli57-61. Synergistic activity 
of phages has also been observed with chemicals other than 
antibiotics as well. The synergistic effect of honey in prevention 
of emergence of phage resistant phenotypes was demonstrated 
in E. coli biofilms62. In milk, two Listeria phages showed 
synergy with bacteriocin coagulin C23 to inhibit Listeria 
monocytogenes63. Synergy amongst phage endolysin LysH5 and 
nisin was also demonstrated to kill Staphylococcus aureus66. 
Phage endolysins have also shown synergistic effects with 
antimicrobials. Ibarra-Sánchez65, et al. recently demonstrated 
a strong synergistic effect amongst endolysin PlyP100 and 
nisin in prevention of Listeria monocytogenes. Similarly, 
LysABP-01 endolysin showed synergistic activity with colistin 
against A. baumanii66. Synergy between LysK and Lysostaphin 
(a staphylococcal bacteriocin) was also demonstrated in 
killing MRSA67.
8. chAllEngEs foR PhAgE ThERAPy
Despite a generous use of clinical phages, the phage 
therapy is still not proliferating due to some constraints, one 
of which is the status of ‘Phage Banks’ and the extent to which 
well-characterised bacteriophages are maintained in them. 
Most of the bacteriophage banks are having a very less number 
of well characterised phages in terms of genomic, proteomic 
and biophysical properties. Secondly, a very low interest of 
pharmaceutical companies in bacteriophages leading to the 
unavailability of phage preparations on pharmacy shelves 
poses a major constraint. Most of the companies involved in 
bacteriophage production have limited themselves to the phage 
mediated biocontrol only such as: Intralytix (US), Micreos 
Food Safety (Netherlands), Omnilytics (US), Phagelux 
(China) & Technophage (Portugal). However some companies 
provide phage lysates and enzybiotics such as Delmont 
laboratories (US) and Gangagen (US/India) or Lysando GmBH 
(Liechtenstein). The lack of approved guidelines for clinical 
and therapeutic use of bacteriophages in clinical settings 
poses another major challenge for phage therapy. Further 
the phage host range and development of bacterial resistance 
pose another important challenge. The bacterial resistance 
may arise due to either a point mutation leading to change of 
surface receptor or by acquisition of capacity to degrade the 
entering phage DNA by restriction endonucleases / mediated 
by clustered regularly interspaced short palindromic repeats 
system (CRISPR) or due to host abortive infection (abi) systems 
causing cell death before progeny phage release68. Transfer of 
AMR genes mediated by transduction through bacteriophages 
is also a hurdle. Another important challenge to phage 
therapy is the problem of producing clean phage (endotoxin 
free) and the lack of data of animal and human studies as 
most of the phage studies have remained restricted to in 
vitro experimentation. 
To overcome the above mentioned constraints, phage 
researchers have presented proofs and arguments to 
advocate the use of phage therapy. New phage banks have 
been established in recent past and the phage banks can be 
better supported financially in immediate future to undertake 
research projects for detailed investigation of bacteriophage 
genomes. This will provide data for selection of better phage 
candidates lacking undesirable genes such as virulence, 
ARGs and lysogeny associated. The issue of resistance 
evolution against a phage is not of magnitude equivalent to 
antibiotic resistance owing to co-evolving nature of phages 
as it will always remain easy to isolate corresponding phages 
from environmental sources in comparison to discovering 
new drug molecules. The constraint of narrow host range 
can be dealt by application of phage cocktails. The virulent 
phages for constituting the cocktail should be selected so 
as to target different host receptors to decrease the rate of 
resistance development69. The use of phage encoded genes 
such as virion-associated phage hydrolases (VAPH) and 
cell envelope digesting proteins or endolysins70,71 also 
offer a suitable alternative. During years of phage therapy, 
methods have also been evolved for production of safe and 
clean endotoxin free phage preparations72. As such there are 
ample reasons and scope to overcome challenges to support 
bacteriophage therapy and research.
9. REgulAToRy IssuEs In PhAgE 
ThERAPy
For medical practitioners seeking to use bacteriophages 
for treatment of MDR infections, the major hurdle encountered 
is the lack of any specific framework, documentation 
and guidelines on phage application as they do exist for 
conventional drugs. Even after almost a century of historical 
data on bacteriophages and accumulated evidences of their 
successful clinical applications, there are no specific guidelines 
for phage application world over. The fact that the drug 
selection for human application is a stringent process, the data 
presented on bacteriophage applications over decades does not 
classify into properly controlled studies. However with the 
newly reported successful human cases of phage therapy73, it 
is being advocated that the categorisation of bacteriophages 
as a classical medicinal product is inappropriate and their use 
should be allowed on compassionate grounds which should 
not be undergoing strict regulatory monitoring. Phage Therapy 
Unit (PTU) in Wroclaw, Poland has been collecting phages 
against 15 different pathogenic bacteria and phage therapy 
has continued there since the year 1970 under the national 
regulatory framework for specific medical conditions. Their 
experience gathered over years about phage therapy may 
be of great significance to the entire world for establishing 
phage therapy in humans. The summary of their experiences 
about phage therapy is also published periodically74,75. 
The regulations of European Union and Food and Drug 
Administration (FDA), USA classify bacteriophages as 
medicinal products and drugs respectively which means that 
they need to be produced following Good Manufacturing 
Practice (GMP) guidelines which makes phage therapy trials 
more difficult and expensive. In Belgium, Phage therapy 
has been initiated as a magistral preparation since 2018 
under Federal regulatory Authorities76. Center for Innovative 
Phage Applications and Therapeutics (IPATH), University of 
California, was initiated in 2018 after the first case of treatment 
of an MDR systemic infection caused by A. baumannii, was 
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reported11. On case to case basis for difficult to treat infections, 
ethical approvals of medical institution may also help to save 
patients77. As such it seems that there is an elevated appeal 
towards bacteriophages as antimicrobials in the currently 
prevailing era of emerging bacterial resistance and hence for 
adaptation of conventional treatment paradigms to ease the 
stringent regulations for phage therapy. 
10. sTATus of PhAgE ThERAPy In IndIA
The application of bacteriophage therapy in India is also 
expanding now. Though most of the previous studies have 
been carried out in animal models but they will prove to be an 
important contribution to establish phage therapy for human 
applications in Indian scenario. The majority of research 
work has been elaborated for safer delivery and treatment of 
infections of wounds, burns, lungs, soft tissues, etc. and have 
targeted pathogenic MRSA, K. pneumoniae and S. pneumoniae 
majorly in mouse models78-82. It is hard to indicate that the 
guidelines for application and regulation of phage therapy are 
not established by medical agencies in India for compassionate 
use/others. 
11. fuTuRE dIREcTIons foR PhAgE 
ThERAPy
Despite the challenges, bacteriophages have remained most 
widely studied amongst all other alternatives to antimicrobials 
available till date. They have demonstrated synergy with many 
compounds and have been found to treat difficult infections. 
There is a renewed interest in bacteriophages and the modern 
techniques of metagenomics, genetic engineering and whole 
geneome sequencing have helped understand, select, design 
and modify bacteriophages. Bacteriophage banks are being 
established as a major resource centre for storage and supply 
of well characterised phages which are being applied for 
personalised medicine. The major challenges in phage therapy 
such as immunological concerns, safety issues and regulatory 
guidelines are being addressed world over. As such it is obvious 
that we remain optimistic about phage therapy. Though it may 
not be able to completely substitute antimicrobial therapy 
in near future yet the opportunity provided by PAS can be 
effectively explored against emerging antimicrobial resistance. 
The role of Phage Banks to allow instant procurement of 
biologically active phages against disease causing bacteria can 
be an immense help to critically ill patients including treatment 
of opportunistic infections in cancer patients. Offering custom 
made phage cocktails through Phage Banks may help in 
tackling the ‘face-off’ with infectious agents and may advance 
phage therapy in real terms.
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